US Patent

US12161628 — Combination therapy

Method of Use · Assigned to Astellas Pharma Inc · Expires 2037-02-23 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent provides a dosage regimen for co-administering enzalutamide with a strong CYP3A4 inducer.

USPTO Abstract

This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer.

Drugs covered by this patent

Xtandi (enzalutamide) · Astellas Pharma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4102`	—	Xtandi
`U-4101`	—	Xtandi
`U-4101`	—	Xtandi

Patent Metadata

Patent number: US12161628
Jurisdiction: US
Classification: Method of Use
Expires: 2037-02-23
Drug substance claim: No
Drug product claim: No
Assignee: Astellas Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.